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INTRODUCTION 
The development of inhibitors to factor VIII 
(FVIII) has become one of the most serious 
complications in the treatment of hemophilia 
patients, occurring in 15-30% of haemophilia A 
(HA) patients and 1-3% of haemophilia B 
(HB) patients. 
The management of acute bleeding episodes 
may use different approaches: human factor 
VIII or factor IX, porcine factor VIII, 
prothrombin complex concentrates (PCC), 
activated prothrombin complex concentrates 
(APCC) and more recently recombinant 
activated factor VII (rFVIIa; NOVOSEVEN). 
rVIIa is a potent by-passing agent which 
mechanism of action is most probably to 
provide a full thrombin burst, in the absence of 
FVIII/FIX, on the activated platelets and 
represents a major therapeutic advance in the 
treatment of haemophilia patients with high-
titer inhibitor. 
Retroperitoneal haemorrhage is a significant 
cause of occult bleeding in the severely 
affected haemophiliac and is associated with a 
high morbidity and mortality in patients with 
factor VIII inhibitors. Survival of the patient 
often depends on rapid accurate diagnosis and 
replacement therapy. 
We report a case of a retroperitoneal 
haemorrhage in a patient with haemophilia A 
and inhibitors, successfully treated with 
rFVIIa. 
 
MATERIAL AND METHODS 
 rFVIIa was given in BII, 96mcg/Kg every 2 
hours, initially, with progressive prolongation 
of the intervals between doses (3-4-6 h), during 
9 days.  
Epsilon-aminocaproic acid (Epsicapron), was 
given, 50mg/Kg, intravenously every 6 hours 
initially and, in oral doses until the patient was 
discharged. 
Laboratory monitoring included platelet count, 
estimations of activated partial thromboplastin 
time (APTT), prothrombin time (PT/INR) and 
factor VII:C levels. 
Both FVII:C and PT/INR were performed by a 
one-stage assay, using a rabbit brain 
thromboplastin. 
CASE DESCRIPTION 
 A 30-year-old haemophilia A patient, with a 
long-lasting high titre inhibitor (actual inhibitor 
titre - 10.5 BU), was admitted to the hospital 
because of intense abdominal and loin pain, 
pallor, marked tachycardia and low blood 
pressure. 
A CT scan revealed a large retroperitoneal 
hematoma, extending along the iliopsoas, 
bilaterally. 
He was treated with recombinant activated 
FVII (rFVIIa), a loading dose of 96mcg/Kg, 
followed by a maintenance dose of 96mcg/Kg, 
in Bolus Intermitent Infusion (BII), every 2 
hours, during the first 24 hours, with 
progressive prolongation of the intervals 
between doses (3-4-6 h). 
In the first two days he received 5 units of 
packed red blood cells (PRBC), because of an 
excessively low hemoglobin level at entry (Fig. 
1). 
Therapy with rFVIIa was maintained during 9 
days and  epsilon-aminocaproic acid at day 10, 
when the patient was discharged. 
 
RESULTS AND CONCLUSION  
The clinical response was excellent in this 
patient with evident relief of pain and better 
mobilization in bed, less than 24 hours after the 
beginning of the treatment. 
At the second day his haemoglobin stabilized 
and no further transfusions with PRBC were 
needed (Fig.1). 
The therapy was prolonged during nine days 
and a total amount of 24000 KUI (480mg) was 
given.  
The PT-INR kept within a range of 0.68-0.52 
and FVII:C levels ranged between 12.3 U/ml 
and 17.7/ml which were within our target range 
(Table 1). 
The APTT decreased max 18.6 sec. as the 
baseline value (range 49.4-68 sec.) 
Other haemostatic parameters did not change. 
Adverse reactions, such as phlebitis or other 
side effects were not reported. 
rFVIIa proved to be very safe and efficacious, 
but in view of the high treatment costs, 
especially when administered as bolus 
injections, the possibility of continuous 
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Fig.1-Hemoglobin levels and PRBC transfusions 
Fig.2 –FVII:C levels and rFVIIa administered. 
Table 1 – Coagulation parameters 
Abdominal CT scan: extensive retroperitoneal hematoma which causes left kidney 
deviation and ilio-psoas thikening (upper) and 50 days later (down). 
 
